3 Mid-Cap Medical Stocks Outperforming the Market Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness. MarketBeat · May 6, 2025
Chart of the Day: ADMA Biologics - Hitting New Highs The Chart of the Day belongs to the biomedical company ADMA Biologics (ADMA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart... Barchart · May 6, 2024
Why ADMA Biologics Shares Are Rising Today ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center. Benzinga · Jun 27, 2022
Looking Into ADMA Biologics's Return On Capital Employed Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter. Benzinga · Jun 16, 2022
Recap: ADMA Biologics Q1 Earnings ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated earnings by 25.0%, reporting an EPS of $-0.1 versus an estimate of $-0.08. Benzinga · May 11, 2022
Earnings Outlook For ADMA Biologics ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08. Benzinga · May 10, 2022
ADMA Biologics's Return On Capital Employed Overview According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million. Benzinga · Mar 25, 2022
ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022. Benzinga · Mar 25, 2022
ADMA Biologics's Earnings Outlook ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.09. Benzinga · Mar 23, 2022